Sotgia Federica, Woodman Scott E, Bonuccelli Gloria, Capozza Franco, Minetti Carlo, Scherer Philipp E, Lisanti Michael P
Department of Molecular Pharmacology, The Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Am J Physiol Cell Physiol. 2003 Nov;285(5):C1150-60. doi: 10.1152/ajpcell.00166.2003. Epub 2003 Jul 2.
Four different phenotypes have been associated with CAV3 mutations: limb girdle muscular dystrophy-1C (LGMD-1C), rippling muscle disease (RMD), and distal myopathy (DM), as well as idiopathic and familial hyperCKemia (HCK). Detailed molecular characterization of two caveolin-3 mutations (P104L and DeltaTFT), associated with LGMD-1C, shows them to impart a dominant-negative effect on wild-type caveolin-3, rendering it dysfunctional through sequestration in the Golgi complex. Interestingly, substitution of glutamine for arginine at amino acid position 26 (R26Q) of caveolin-3 is associated not only with RMD but also with DM and HCK. However, the phenotypic behavior of the caveolin-3 R26Q mutation has never been evaluated in cultured cells. Thus we characterized the cellular and molecular properties of the R26Q mutant protein to better understand how this mutation can manifest as such distinct disease phenotypes. Here, we show that the caveolin-3 R26Q mutant is mostly retained at the level of the Golgi complex. The caveolin-3 R26Q mutant formed oligomers of a much larger size than wild-type caveolin-3 and was excluded from caveolae-enriched membranes. However, caveolin-3 R26Q did not behave in a dominant-negative fashion when coexpressed with wild-type caveolin-3. Thus the R26Q mutation behaves differently from other caveolin-3 mutations (P104L and DeltaTFT) that have been previously characterized. These data provide a possible explanation for the scope of the various disease phenotypes associated with the caveolin-3 R26Q mutation. We propose a haploinsufficiency model in which reduced levels of wild-type caveolin-3, although not rendered dysfunctional due to the caveolin-3 R26Q mutant protein, are insufficient for normal muscle cell function.
四种不同的表型与CAV3突变相关:肢带型肌营养不良1C型(LGMD - 1C)、波纹肌病(RMD)、远端肌病(DM)以及特发性和家族性高肌酸激酶血症(HCK)。与LGMD - 1C相关的两种小窝蛋白 - 3突变(P104L和DeltaTFT)的详细分子特征表明,它们对野生型小窝蛋白 - 3具有显性负效应,通过在高尔基体复合物中隔离使其功能失调。有趣的是,小窝蛋白 - 3氨基酸位置26处的精氨酸被谷氨酰胺取代(R26Q)不仅与RMD有关,还与DM和HCK有关。然而,小窝蛋白 - 3 R26Q突变的表型行为从未在培养细胞中进行过评估。因此,我们对R26Q突变蛋白的细胞和分子特性进行了表征,以更好地理解这种突变如何表现为如此不同的疾病表型。在这里,我们表明小窝蛋白 - 3 R26Q突变体大多保留在高尔基体复合物水平。小窝蛋白 - 3 R26Q突变体形成的寡聚体比野生型小窝蛋白 - 3大得多,并且被排除在富含小窝的膜之外。然而,当与野生型小窝蛋白 - 3共表达时,小窝蛋白 - 3 R26Q并没有表现出显性负性作用。因此,R26Q突变的行为与先前已表征的其他小窝蛋白 - 3突变(P104L和DeltaTFT)不同。这些数据为与小窝蛋白 - 3 R26Q突变相关的各种疾病表型范围提供了一种可能的解释。我们提出了一种单倍剂量不足模型,其中野生型小窝蛋白 - 3的水平降低,尽管由于小窝蛋白 - 3 R26Q突变蛋白而未使其功能失调,但仍不足以维持正常的肌肉细胞功能。